Government of Germany   Report issue

Government Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2002
NCT00167843
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bavarian State Ministry of Health and Care | Bavarian State Office for Health and Food Safety | Bayerisches Staatsministerium für Wirtschaft und Medien, Energie und Tehchnologie | Bundesministerium fuer Bildung und Forschung (BMBF) | Federal Agency for Disruptive Innovation - SPRIN-D | Federal Institute for Occupational Safety and Health (BAuA)/Germany) | German Centre for Assessment and Evaluation of Innovative Techniques in Medicine | German Federal Armed Forces | Innovation Fund of the Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA), Germany | Ministry of Innovation, Science and Research in North Rhine-Westphalia | The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit, BMG)

Active Ingredients

Drugs in Phase 4 Trials (4)

empagliflozin (jardiance) (1 trial)

pyrimethamine (daraprim) (1 trial)

semaglutide (Ozempic) (1 trial)

sulfadoxine (1 trial)

Drugs in Phase 3 Trials (1)

fluoroethylcholine (1 trial)

Drugs in Phase 2 Trials (3)

camostat mesylate (1 trial)

contraloid (2 trials)

COVID-19 convalescent plasma (1 trial)

Drugs in Other Trials (1)

enrofloxacin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fatty Liver (Phase 4)

Infections (Phase 2)

Liver Diseases (Phase 4)

Malaria (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Respiration Disorders (Phase 2)

Respiratory Tract Diseases (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 9